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Abstract 
Skeletal muscle differentiation (myogenesis) is the process of converting mono-nucleated 
myoblast cells into multinucleated differentiated myotubes that form the basis of the skeletal 
musculature. Myogenic regulatory factors (MRFs) are sequence specific, DNA binding 
transcription factors that play a central role in myogenesis. Two of the MRFs, MyoD and 
Myogenin, are essential to the initiation of the irreversible differentiation program. TGFβ is the 
prototypic member of the TGFβ super-family of cytokines and a potent inhibitor of myogenesis. 
Inhibitory Smads (I-Smad) repress receptor regulated Smads (R-Smads) activation by TGFβ and 
exogenous expression of Smad7 (one of the two I-Smads) enhances myogenesis as indicated by 
premature expression of myogenic marker genes such as myogenin, mck, and myhc. 
Previously, our group showed that exogenously expressed nuclear Smad7 was able to 
induce early myogenesis, indicating that Smad7 has a role in the nucleus, separate from its 
cytoplasmic function and this role contributes to its enhancing properties on myogenesis. A 
recent screen for Smad7 interacting proteins indicated an interaction between Smad7 and 
SET/TAF-Iβ, a nuclear protein which plays diverse functions in chromatin remodeling, cell 
cycle, autophagy, and apoptosis. The focus of this study was to characterize the roles of Smad7 
and SET, and the interaction of the two impacts myogenesis. Here we report that ectopic 
expression of SET inhibits myogenic differentiation. However, co-expression of SET and Smad7 
resulted in a strong enhancement of myogenesis, leading to the formation of more robust 
myotubes and higher levels of myogenic markers. Using ChIP-qPCR, we quantified levels of 
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activating and repressive histone marks on regulatory regions of several muscle specific genes 
such as myogenin and muscle creatine kinase (mck).  
These data indicate that expression of exogenous SET alone led to higher levels of 
transcriptionally repressive marks (H3K27me3) and lower levels of activating marks 
(H3K4me3/H3K9Ac) on muscle specific regulatory regions. Contrary to the effects seen with 
SET alone, expression of exogenous Smad7 resulted in higher levels of transcriptionally 
activating marks (H3K4me3/H3K9Ac) and lower levels of the transcriptionally repressive mark 
(H3K27me3) compared to that of control. Interestingly, co-expression of exogenous SET and 
Smad7 led to higher levels of transcriptionally activating marks (H3K4me3/H3K9Ac) while also 
exhibiting lower levels of the transcriptionally repressive mark (H3K27me3) compared to that of 
Smad7 alone.  
Taken together these data indicate that SET can function as an inhibitor of transcription 
for myogenic related genes, while the interaction with Smad7 relieves, and enhances 
transcription of those myogenic genes. In contrast to the “myogenic” genes, exogenous Smad7 
had no effect on SET’s capability to repress the cyclin D1 promoter. This may explain the 
enhancement of myogenesis with SET and Smad7 together since cell cycle withdrawal, which is 
mediated by cyclin D1 suppression, is a prerequisite of differentiation. Therefore, SET mediated 
repression of cell cycle coupled with Smad7’s antagonism of SET at myogenic genes results in a 
pronounced enhancement of myogenesis. These observations further explain the role of Smad7 
in the molecular control of myogenesis, having wider implications for understanding skeletal 
muscle physiology and pathology. 
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Review of Literature  
Origin of skeletal muscle  
Skeletal muscle is an essential tissue that allows locomotion and supports the proper posture for 
vertebrates. With the exception of some facial and oesophageal muscles, all skeletal muscle 
fibres of the body come from progenitor cells that originate from somites. Somites are transient 
spheres of cells that originate from the paraxial mesoderm, forming on either side of the neural 
tube during ontogeny.  
These newly formed epithelial cells are divided further into distinguishable groups of cells such 
as the sclerotome, syndetome, dermomyotome, and the myotome. (Figure 1B) The syndetome 
gives rise to tendons while the sclerotome gives rise to bones and cartilage. The dermomyotome 
gives rise to dermis and to the progenitor cells of the myotome and the cells at the epaxial 
myotome give rise to the deep back muscles while the hypaxial dermomyotome provides muscle 
precursor cells that migrate and form the skeletal musculature of the limbs and the lateral trunk 
muscles (Brent et al., 2003, Brent and Tabin, 2002, Buckingham et al., 2003). 
The progenitor cells in the ventral lateral lip delaminate from the dermomyotome, migrate into 
the anatomical positions that muscle fibres must form on the limbs, where they proliferate, 
express myogenic determination factors and subsequently differentiate into myotubes (Figure 
1A) (Ordahl and Le Douarin, 1992, Marcelle et al., 1997). 
The differentiated myotubes are multinucleated cells expressing muscle specific gene markers 
such as muscle creatine kinase (mck) and myosin heavy chain (myhc) which contribute to the 
final stage of muscle development, the maturation of myotubes into muscle fibres. 
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Figure 1: Schematic diagram showing the origin of skeletal muscle in the developing 
embryo and the different stages of skeletal muscle differentiation. Images adapted from 
(Staveley, 2010, Miyake, 2009, Sindhu, 2014) 
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Molecular biology of skeletal muscle development 
Pax3 in skeletal muscle specification 
The paired box gene family is characterized by the presence of a paired domain. The 
Paired box gene-3 (Pax3) is widely expressed in the presomitic mesoderm and is also found in 
newly formed epithelial somites. Pax3 is the first known protein that is involved in specification 
of the skeletal muscle lineage (Chi and Epstein, 2002, Marcelle et al., 1997, Lang et al., 2007). 
Exogenous in vitro expression of Pax3 in the lateral mesoderm induces expression of both 
myogenic differentiation 1 (MyoD) and myogenic factor-5 (Myf5), two downstream 
transcription factors that play major roles in the commitment and differentiation of muscle cells 
(Marcelle et al., 1997). 
Embryos lacking the Pax3 protein (Pax3-/-) don’t form limb muscles, suggesting that 
Pax3 is required for the migration of the precursor cells from the ventral lateral lip (VLL) of the 
hypaxial dermomyotome to the limbs (Goulding et al., 1994). Furthermore, embryos lacking 
Pax3 and Myf5 proteins fail to form muscle anywhere except some head muscles. This suggests 
that Pax3 regulates the initiation of the myogenic gene expression program since the myf5 gene 
is also regulated by Pax3 (Tajbakhsh et al., 1997). Indeed, exogenous expression of Pax3 was 
sufficient enough to convert mesoangioblasts and P19 embryonic carcinoma cells into the 
skeletal muscle lineage (Ridgeway and Skerjanc, 2001). 
It is important to note that Pax3 expression is only important to initiate the myogenic 
gene expression program as Pax3 expression has not yet been detected in adult skeletal muscles, 
with the exception of a small fraction of musculatures and satellite cells (Lepper et al., 2009). In 
fact, exogenous Pax3 inhibits the normal course of myogenesis in C2C12 cells (Epstein et al., 
1995). Even in satellite cells, Pax3 is only transiently upregulated upon activation and 
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proliferation, suggesting that Pax3 may only be required for activation and early proliferation, 
but Pax3 levels need to be downregulated for progression of myoblast differentiation (Boutet et 
al., 2007). 
Pax7 in skeletal muscle development 
 Another essential member of the Pax gene family is Pax7, and the canonical view is that 
Pax7 is a major player in specification and survival of satellite cells (Seale et al., 2000). Pax7 
was found to be expressed in the central region of the dermomyotome (Figure 2), and has been 
shown to compensate some of Pax3’s role in the dorsal neural tube, neural crest cell, and somite 
development (Mansouri et al., 1996). However, loss of Pax7 let to complete loss of satellite cells 
resulting in regeneration defects in the postnatal mouse (Seale et al., 2000). Loss of both Pax3 
and Pax7 causes complete arrest in skeletal muscle development after the primitive myotome is 
formed (Relaix et al., 2005). It is evident that Pax7 is essential for satellite cell survival and Pax3 
is required for migration of muscle progenitor cells to the limb and commitment to the myogenic 
lineage. 
Specification of skeletal muscle progenitors  
The newly formed epithelial somites are divided into pools of progenitor cells, with the 
myotome giving rise to the skeletal muscle in the body. Specification of the myotome is highly 
dependent on the position of the cells in the newly formed somite, and communication with the 
surrounding axial structures by means of extracellular protein-protein interactions or soluble 
secreted factors are required for commitment into the myotome progenitor pool (Marcelle et al., 
1997). 
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Figure 2: Major cell-cell communications at the dorsal medial lip (DML) in the developing 
embryo. Adapted from (Miyake, 2009). 
One of the key players in specification of the myotome is the sonic hedgehog (Shh) 
protein, which is secreted from the notochord and the floor plate of the neural tube and is 
required for activating the transcription factor Myf5 in the dorsal medial region (DML) and 
epaxial myotome. Wnt signalling from the neural tube also contributes to the specification of 
DML by activating the Noggin and Gli transcription factors that further activate Myf5. 
Conversely, the neural tube secretes Bone Morphogenetic Proteins (BMPs) which inhibit Myf5 
expression in the hypaxial myotome. However, since Noggin, an antagonist of BMP signalling is 
present due to Wnt signalling, BMP signalling is unable to inhibit Myf5 in the DML (Fan et al., 
1995, Gustafsson et al., 2002, Johnson et al., 1994, Münsterberg et al., 1995). 
The high BMP levels from the dorsal ectoderm keep the hypaxial muscle precursors in an 
undifferentiated state due to BMPs ability to successfully inhibit Myf5 expression in hypaxial 
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muscle progenitors. However, since Wnt signaling induces both Gli (agonist of Myf5), and 
Noggin (antagonist of BMP), myf5 gene expression is still induced in the DML (Cossu et al., 
1996, Pourquié et al., 1995, Pourquié et al., 1996, Schnapp et al., 2009, Sporle et al., 1996, 
Takada et al., 1994). 
The ventral region of the somites also have Myf5 since the Shh secretion from the 
notochord and floor plate of the neural tube induce Myf5 expression. Myf5 presence in these 
progenitor cells results in expression of MyoD, a major skeletal muscle transcription factor that 
guides the cells to differentiate into myotubes.  
The notochord and the floor plate of the neural tube therefore play a pro-differentiation 
role in the formation of myocytes and epaxial muscles on the ventral side while the dorsal end of 
the neural tube along with the dorsal ectoderm keep the progenitor cells in a proliferative and 
undifferentiated state, contributing to a growing dermomyotome (Figure 2) (Cossu et al., 1996). 
Myogenic regulatory factors (MRFs) in skeletal muscle development 
The four myogenic regulatory factors, Myf5, MyoD, MyoG, and MRF4 are essential to 
the induction of the skeletal muscle differentiation program (Yokoyama and Asahara, 2011). The 
four MRFs are part of the basic helix-loop-helix (bHLH) family of transcription factors and are 
evolutionarily conserved in vertebrates (Pownall et al., 2002). The MRFs have been shown to 
have the remarkable ability to convert many nonmuscle cell type into muscle which identifies 
these transcription factors as key regulators of the differentiation of muscle progenitor cells 
(Davis et al., 1987, Molkentin and Olson, 1996). Myf5 and MyoD are highly expressed in the 
proliferating myoblasts while Myogenin and MRF4 are expressed at later stages of 
differentiation, suggesting that Myf5 and MyoD establish and maintain the muscle progenitor 
lineages while Myogenin and MRF4 induce expression of muscle contractile genes including 
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MyoD and Myf5. Most skeletal muscle specific genes have the a short consensus DNA sequence 
CANNTG, termed E-box, in their regulatory region and to induce promoter activity of the genes, 
this sequence needs to be bound by ubiquitously expressed E-proteins (E12, E47) and a 
heterodimer complex of the MRFs (Etzioni et al., 2005, Murre et al., 1989). 
The importance of the function of the MRFs for myogenesis is revealed when looking at 
the gene targeting studies in mice. Loss of MyoD (Rudnicki et al., 1992) or Myf5 (Braun et al., 
1992) alone has no effect on specification of the myogenic lineage in embryo development. 
However, mice lacking both MyoD and myf5 leads to loss of myoblast and muscle fibers 
prevailing the importance of Myf5 and MyoD in cell lineage specification (Kassar-Duchossoy et 
al., 2004). 
In contrast to mice lacking MyoD and myf5, the early steps of myogenesis occurs 
normally in mice lacking myogenin. However, secondary myogenesis, which leads to the 
formation of myofibers, does not take place in myogenin mutants, and myogenin(-/-) mice die 
prenatally because of the complete absence of differentiated muscle. Instead of myotubes 
containing multinucleated myocytes, only mononucleated cells are present in muscle tissue of 
myogenin(-/-)  mice (Hasty et al., 1993). 
Mutations of mrf4 result in largely varied phenotypes, from minor rib cage defects in 
viable mice, to perinatal lethality of mice (Patapoutian et al., 1995, Zhang et al., 1995). Since the 
MRF4 and Myf5 locus are within 8kb of each other in mice, any mutation on mrf4 affects the 
expression of the myf5 gene leading to phenotypes similar to mutations on myf5 that 
downregulate myf5 expression. (Yoon et al., 1997) As a result, it appears likely that the rib 
phenotype observed in mrf4 mutants was not because of the loss of MRF4 function, but caused 
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by the down regulation of Myf5. The function of MRF4 needs to be elucidated further before any 
clear, distinct function for MRF4 is established.  
MEF2 transcription factors in skeletal muscle development 
In mammals, there are four mef2 genes mef2a-d. The MEF2 proteins form homo or 
heterodimers on dsDNA, on a consensus sequence [(C/T)TA(A/T)4(TA(G/A)], termed the MEF2 
binding site (Pollock and Treisman, 1991). In vivo studies revealed that the mef2 genes are 
expressed in developing cardiac, skeletal, and smooth muscle cells during embryogenesis but are 
downregulated after birth, suggesting that the mef2 genes act synergistically with MRFs to 
activate muscle specific genes and induce myogenic determination and differentiation. (Black 
and Olson, 1998, Olson et al., 1995). Indeed, mef2 genes have been shown to activate several 
muscle specific genes and when introduced in combination with MRFs, increase efficiency of 
myogenic conversion of non-muscle cells in vitro. mef2 genes are expressed in a wide variety of 
tissues after E12.5, suggesting that the activity of MEF2 is post transcriptionally regulated 
(Ornatsky and McDermott, 1996). MEF2 transcriptional activity was shown to be regulated by 
phosphorylation and recruitment of either Histone acetyltransferase (HAT) or histone 
deacetylases (HDACs) (Du et al., 2008). 
Most muscle specific genes have, within their regulatory region, both a conserved E-box 
and MEF2 binding site for MRF and MEF2 members to bind respectively. MEF2 and MRFs 
have been shown to work together synergistically to upregulate these muscle specific genes in 
muscle cells, presumably to induce determination and differentiation (Black and Olson, 1998, 
Olson et al., 1995). 
9 
 
The Transforming Growth Factor β (TGFβ) Signaling pathway 
One of the key regulators of tissue morphogenesis and embryonic development is the 
TGFβ superfamily, which consists of TGFβs, BMPs, Nodal, Activin, and Growth and 
differentiation factors (GDFs). Active TGF-β ligand dimers bind to TGFβ cell surface receptors, 
phosphorylating intracellular effector proteins (receptor Smads; or R-Smads), which translocate 
into the nucleus and regulate target gene expression that leads to a cellular response (Feng and 
Derynck, 2005, Heldin et al., 1997). 
TGFβ has been found to have a regulating role in proliferation, migration, adhesion, 
apoptosis, cell growth and differentiation. For example, TGFβ stimulation induces fibrosis and 
proliferation of fibroblasts (Hocevar et al., 2005), enhances differentiation of neuronal cells 
(Moon et al., 2009) but blocks differentiation in mesenchymal cells (Bakin et al., 2000).  It is 
apparent that the cellular context in which the TGFβ signalling is activated is what dictates the 
end effect (Feng and Derynck, 2005). 
Most cell types express TGF-β family members as they play key roles in differentiation 
and tissue morphogenesis. Responses to TGFβ stimulation are complex due to the high number 
of possible different ligands and receptor complex formations which depend on the cell context 
and physiological environment.  
There are over 42 ligands from 29 genes that encode the TGFβ superfamily ligands that 
are believed to be secreted out of the synthesizing cell as homo or heterodimers (Shi and 
Massagué, 2003, Derynck and Zhang, 2003) (Figure 3) . 
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Figure 3: Schematic diagram of TGFβ ligand/receptor combinations. Adapted from 
(Miyake, 2009) 
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TGFβ ligand processing and receptor interaction 
Upon synthesis, the long peptide chain product of the tgfβ gene is cleaved via Furin, a 
proprotein convertase, creating a complex called the Small Latent Complex (SLC) (Derynck et 
al., 1985, Rifkin, 2005). The SLC and Latent TGFβ-binding protein (LTBP) combine to form the 
Large Latent Complex (LLC). The LLC is what gets secreted into the extracellular matrix 
(ECM) (Annes et al., 2003). The Latency Associated Peptide (LAP) and LTBP proteins act as an 
extracellular trap that isolates TGFβ ligands, preventing any interaction with the TGFβ surface 
receptors. In order for the ligands to bind to TGFβ surface receptors, the ligands need to be 
released from the LLC, usually by a secreted enzyme such as Matrix metalloproteinases 2/9 
(MMP-2, MMP9) (Yu and Stamenkovic, 2000) or Thrombospondin-1 (Schultz-Cherry and 
Murphy-Ullrich, 1993). Alternatively, acidic conditions (Lyons et al., 1988) or reactive oxygen 
species (Barcellos-Hoff and Dix, 1996) can also induce the release of the TGFβ ligands from the 
LLC and the active TGFβ ligand can then bind to and activate a receptor complex. (Figure 4)  
Figure 4: Schematic diagram of TGFβ ligand processing and activation. 
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The TGFβ cell surface receptor complex contains two ‘type I’ and two ‘type II’ 
transmembrane proteins. The type I & II TGFβ receptors have a structurally similar structure 
with the major difference being a Glycine/Serine-rich ‘GS-rich sequence’ in the cytoplasmic tail 
of the type I receptor. Without ligand binding, the TGFβ receptors form homodimers and are 
inactive kinases. Once the LLC is cleaved and the active TGFβ ligands are released, the ligands 
are able to bind to the TGFβ receptor complex. Binding of the TGFβ ligand to the type II 
receptors stimulates recruitment of two type I receptors, followed by auto-phosphorylation of 
serine residues in the ‘GS-rich sequence’ of the type I receptor, forming an activated receptor 
complex (Shi and Massagué, 2003). 
So far, seven type I and six type II receptors have been identified, generating a high 
number of diverse receptor complexes which explains the ligand specificity and diverse 
biological responses. Some of the ligand/receptor combinations of the TGFβ family cytokines 
are shown in Figure 3. In most cases, the TGFβ ligands in the canonical TGFβ signalling 
pathway activate R-Smads 2, and -3 while the BMP ligands activate receptor complexes such as 
BMPRII that recruits R-Smads 1, -5, and -8 (Shi and Massagué, 2003). The cellular response to 
TGFβ stimulation is dictated by the expression of different receptor types by the cell before the 
TGFβ stimulation. 
The ‘Canonical’ TGFβ signalling pathway through R-Smads 
The intracellular signalling molecules of the TGFβ ‘canonical’ signalling pathway are the 
Mothers against decapentaplegic (Smad) proteins. The Smad proteins are functionally 
categorized into three groups: the receptor Smads (R-Smad 1, 2, 3, 5, and 8), the Common-Smad 
(C-Smad, Smad4), and the inhibitory Smads (I-Smads, Smad6 and 7). There is a conserved MH2 
(Mad Homology 2) domain in the C-terminus of all the Smads with the L3 loop in the MH2 
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domain responsible for binding to a specific type I receptor in the activated receptor complex. 
There is a less conserved MH1 domain in the N-termini of the Smad proteins responsible for 
interaction with DNA (Macias et al., 2015, Shi and Massagué, 2003) (Figure 5). 
 
Figure 5: Schematic diagram of different domains in Smad proteins. 
Upon activation of the receptor complex, R-Smads are recruited to the cytoplasmic tail of 
the type I receptor, at which both serines in the SXS motif in the C-terminus end of the R-Smads 
are phosphorylated. This causes a conformational change that dissociates the R-Smads from the 
receptor complex and the phosphorylated R-Smads bind to the Co-Smad, Smad4, forming what 
is termed the RC-Smad complex. TAZ (Transcriptional co-activator with PDZ-binding motif) is 
also recruited to the RC-Smad complex and is suggested to be required for the translocation of 
the RC-Smad complex into the nucleus (Varelas et al., 2008) (Figure 6). 
Once in the nucleus, the RC-Smad complex is able to bind to its consensus DNA 
sequence (GTCTAGAC) with, Smad3 in particular, binding to the Smad Binding Element (SBE) 
sequence (5’ GTCT 3’) (Shi et al., 1998). Interestingly, the interaction between the RC-Complex 
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and the SBE is weak, which is why the target promoters usually have the SBE adjacent to 
binding sites of other transcription factors that associate with the RC-Smad complex. The RC-
Complex can interact with a wide variety of DNA binding transcription factors, transcriptional 
co-activators and co-repressors, which is why the context in which the TGFβ signalling pathway 
is activated dictates the cellular response (Shi and Massagué, 2003, Heldin et al., 1997, 
Massagué, 1996). 
For example, the transcriptional activation properties of the R-Smads relies on the 
recruitment of CBP (CREB binding protein/p300) (Feng et al., 1998, Guannan et al., 2005). 
Along with CBP, the RC-Smad complex containing Smad2/3 recruit P/CAF (P300/CBP 
associated factor) and GCN5 while only GCN5 is recruited to the RC-Smad complex containing 
Smad1, 5, 8 (Itoh et al., 2001, Kahata et al., 2004). Another example of the diversity seen in 
interacting partners of the RC-Smad complex is the recruitment of BRG1 that is required for the 
upregulation of TGFβ response genes in epithelial cells. The BRG1-RC-Smad complex is able to 
recruit the SWI/SNF complex to the target promoter and this recruitment is required to initiate 
target gene expression (Xi et al., 2008). 
Inhibitory I-Smads 
An interesting feature of this signalling pathway is the existence of inhibitory Smads (I-
Smads; Smad6 and Smad7) that repress the canonical TGFβ pathway by physically binding to 
the activated cytoplasmic tail of the Type I receptor, while being prone to phosphorylation due to 
a lack of the SXS motif seen in R-Smads (Hayashi et al., 1997, Goto et al., 2007) (Figure 5). 
 Since I-Smads lack the phosphorylation motif, they are unable to undergo the same 
conformational change that R-Smads require to dissociate from the receptor complex. As a 
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result, I-Smads inhibit the formation of the RC-Smad complex and the subsequent downstream 
effects by inhibiting the TGFβ receptor activity (Shi and Massagué, 2003). 
Smad6 in TGFβ signaling 
Smad6 is the inhibitory Smad for the BMP Signalling pathway, binding to the type I 
BMP receptors and blocking phosphorylation of Smad1, and 2. However, an alternative 
inhibitory mechanism was suggested by another group where Smad6 doesn’t have an effect on 
the phosphorylation of Smad1 and binds to Smad4 instead, preventing the formation of the RC 
complex. Additional mechanisms aside from inhibiting the BMP receptor complex have been 
proposed for Smad6 with studies indicating an interaction with the glucocorticoid receptor (GR) 
and subsequent recruitment of HDAC3, resulting in suppression of any GR facilitated 
transcriptional activity. Furthermore, Smad6 was shown to bind to DNA and recruit Class I 
HDACs, inhibiting expression of BMP stimulated genes (Goto et al., 2007). 
Smad7 in TGFβ signaling 
Smad7, another I-Smad, which structurally resembles Smad6, also has a highly conserved 
MH2 domain and much like Smad6, has a much less conserved MH1 domain (Hayashi et al., 
1997). Although Smad7 hinders the type I BMP receptor’s ability to phosphorylate R-Smads, its 
canonical role is to inhibit the TGFβ /Nodal Signalling by binding to the TGFβ type I receptor, 
preventing Smad2, and Smad3 phosphorylation. Smad7 interacts with the TGFβ type I receptor 
and with Serine/threonine kinase receptor associated protein (STRAP), interfering with the 
physical access of Smad2/3 to the activated TGFβ receptor complex (Datta and Moses, 2000, 
Datta et al., 1998). The C-terminus of the Smad7 protein is essential for the interaction with the 
type I TGFβ receptor (Mochizuki et al., 2004). Pyruvate dehydrogenase Kinase 1 (PDK1) also 
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binds to Smad 2, 3, 4 and 7 and enhances PDK1 kinase activity but reduces the transcriptional 
properties of the R-Smads which suggests that Smad7 and PDK1 might be working together to 
inhibit TGFβ signalling pathway (Seong et al., 2005, Seong et al., 2007). 
 
Figure 6: Schematic Diagram of Canonical TGFβ signalling through Smad proteins. 
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Smad independent, ‘noncanonical’ TGFβ Signalling pathways 
Besides the canonical TGFβ signalling pathway that involves activation of R-Smads, 
TGFβ signalling has also been implicated in the regulation of many other signalling pathways 
including the MAPK and and activate kinase 1 (TAK1) signalling pathway (Shibuya et al., 1996, 
Yamaguchi et al., 1995). TAK1 was shown to bind to the unstimulated TGFβ type I receptor and 
upon ligand stimulation, TAK1 dissociates from the receptor and autophosphorylates to become 
activated. Since TAK1 is an MKKK, it can activate MKK (Ishitani et al., 1999, Ninomiya-Tsuji 
et al., 1999). TGFβ was also shown to activate all three branches of MAPK pathways, p38 
MAPK, JNK, and ERK (Hocevar et al., 2005). TGFβ induction of ECM production and fibrosis 
was shown to be through TGFβ-induced activation of the MKK3-p38 MAPK and MKK4-JNK 
signalling pathways and thus subsequent type I collagen and fibronectin expression respectively 
(Zhang et al., 2000). 
Smad7 regulation 
The expression of the Smad7 gene is enhanced upon TGFβ stimulation, creating a 
negative feedback loop for the canonical TGFβ pathway (Nakao et al., 1997). Ectopic Smad3 is 
able to upregulate Smad7 expression by binding to the SBE in the regulatory region of the smad7 
gene (Denissova et al., 2000). The smad7 gene was also shown to be regulated by AP-1 and Sp1 
in a Smad2/3 dependent way (Brodin et al., 2000). Upon TGFβ stimulation, the transcription 
factor IGHM enhancer-3 (TFE3) was shown to synergistically upregulate the Smad7 gene with 
ectopic Smad3 through the binding of Smad3 to the SBE, and the recruitment of TFE3 to an E-
box in close proximity to the Smad3 bound SBE (Hua et al., 2000, Stopa et al., 2000). 
Smurf2, Tiul, and NEDD4-2 are all E3 ubiquitin ligases that bind to Smad7 and enhance 
its inhibitory effect on TGFβ signalling by targeting the Smad7 bound receptor complex for 
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degradation (Chong et al., 2006, Murakami et al., 2003, Kavsak et al., 2000, Kuratomi et al., 
2005, Seo et al., 2004). AIP4 and Arkadia which are also E3 ubiquitin ligases, bind to Smad7, 
but can only target the Smad7 protein for degradation (Lallemand et al., 2005, Niederländer et 
al., 2001). AIP4 and Arkadia are therefore enhancers of the TGFβ signalling pathway because of 
their ability to target Smad7 for ubiquitination. 
Smurf1 E3 ligase can also bind to Smad7, even when Smad7 is bound to the TGFβ type I 
receptor. This helps bring Smurf1 to close proximity of the TGFβ type I receptor and target the 
TGFβ receptor-Smad7 complex for degradation (Tajima et al., 2003). However, Smad7 itself can 
also be ubiquitinated by Smurf1, even if not bound to the TGFβ receptor (Suzuki et al., 2002). 
Furthermore, Smad7 can also act as a bridging protein for Smurf1 and Smad4, allowing Smurf1 
to also ubiquitinate Smad4 and target it for degradation. Smurf1 can therefore be viewed as both 
an activator, and as a repressor of the TGFβ pathway, depending on the cellular context (Morén 
et al., 2005). 
Another way that Smad7 is able to inhibit TGFβ receptor complex activity is by binding 
to the type I receptor, and recruiting the Growth arrest and DNA damage-34 (GADD34) protein. 
GADD34 is part of the Protein phosphatase 1 protein, which was shown to dephosphorylate, and 
hence deactivate the TGFβ type I receptor (Shi et al., 2004). 
The Smad7 protein can also be regulated via PTM. P300 was shown to acetylate lysine 
residues 64 and 70 and prevent Smurf1 mediated ubiquitination of the same residues, allowing 
stabilization of the Smad7 protein (Grönroos et al., 2002). 
Smad7 sub-cellular localization 
Interestingly, Smad7 was shown to be predominantly localized in the nucleus of 
fibroblast-like COS1 cells and upon TGF-β1 stimulation, Smad7 accumulated in the cytoplasm. 
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The study found that the MH2 domain for Smad7 was required for nuclear localization (Itoh et 
al., 1998, Hanyu et al., 2001). However, another group showed that TGFβ stimulation had no 
effect on subcellular localization of Smad7 in epithelial-like Mv1Lu cells, but subcellular 
localization would depend on the material the cells were cultured in. If the cells were cultured on 
fibronectin coated glass plates or plastic, then Smad7 would predominantly localize in the 
cytoplasm. However, if the cells were cultured on a glass bottom plate, Smad7 would localize 
predominantly in the nucleus (Zhu et al., 1999). 
As mentioned before, Smurf1 is able to ubiquitinate Smad7 regardless if its bound to the 
receptor or not. Ebisawa et al. found that smurf1 mediated ubiquitination of Smad7 can induce 
its translocation into the cytoplasm via a nuclear export receptor termed exportin-1 (CRM-1) 
(Ebisawa et al., 2001). CRM-1 mediated export of Smad7-Smurf1 complex requires the NES of 
Smurf1. Much like Smurf1, Tiul1 was also shown to co-translocate with Smad7 from the nucleus 
into the cytoplasm (Komuro et al., 2004). PDK1 was also shown to interact with Smad7 and 
inhibit its nuclear export (Seong et al., 2007). 
Nuclear function of Smad7 
A number of roles for Smad7 in the nucleus have been reported. Smad7 was shown to 
associate with HDAC-1 in NIH 3T3 fibroblasts, and was able to supress E2F1 transcriptional 
activity through HDAC-1, suggesting Smad7 as a corepressor of E2F1 (Emori et al., 2012). 
Interestingly, ectopic expression of Smad7 was shown to induce cell cycle arrest in a variety of 
mesenchymal cells through down-regulation of G1 cyclins (Emori et al., 2012). Smad7 was 
shown to bind to SBE in the promoter of the plasminogen activator inhibitor-1 (pai1) gene via 
its MH2 domain and prevent R-Smad dependent transcription of pai1 (Zhang et al., 2007). Our 
group previously showed that Smad7 physically binds to and enhances MyoD’s transcriptional 
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properties, promoting skeletal muscle differentiation independent of its inhibitory role on the 
TGFβ signalling pathway (Miyake et al., 2010) (Figure 7). 
 
Figure 7: Schematic diagram of Smad7 nuclear function in skeletal muscle differentiation. 
Pathophysiological roles of Smad7 
Scleroderma, also known as systemic sclerosis, is a chronic systemic autoimmune disease 
leading to excessive fibrosis in the affected internal organs. Sample tissues have shown 
hyperactive TGFβ, Smad2 and Smad3 activity, combined with reduced levels of Smad7. 
Exogenous expression of Smad7 attenuates the chronical activation of the TGFβ signalling 
(Dong et al., 2002). In Tubulointerstitial fibrosis, Smurf1 and Smurf2 are upregulated, and as 
mentioned before, one of their target substrates is Smad7. The upregulation of Smurf1 and -2 
reduces Smad7 levels while enhancing presence of phosphorylated Smad2 and -3 in the nucleus 
(Fukasawa et al., 2004). In contrast, Smad7 is hyperactive in inflammatory bowel disease (IBD), 
causing upregulation of pro-inflammatory cytokines which would normally be downregulated 
via TGFβ signalling (Monteleone et al., 2001). One of the downstream targets of the TGFβ 
signalling pathway is NF-KB, a key transcriptional factor that upregulates pro-inflammatory 
cytokines. TGFβ stimulation induces reduction of NF-Kβ levels. However, in IBD, TGFβ 
signalling can no longer reduce NF-Kβ levels due to high levels of Smad7 (Monteleone et al., 
2004). 
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Laminin α2-deficient congenital muscular dystrophy type 1A (MDC1A), an autosomal 
muscle disease that leads to muscle waste and shortened lifespan. Treatment with Losartan, an 
angiotensin II type I receptor blocker, restored some skeletal remodeling while reducing fibrosis 
(Mehuron et al., 2014). The mechanism suggested for Losartan was by inhibition of the TGFβ 
signalling pathway that resulted in reduced levels of phosphorylated Smad2, -3, while also 
showing decreased TGF-β1 ligand levels. Moreover, Losartan treatment led to higher levels of 
the Smad7 protein (Elbaz et al., 2012). 
Role of TGF-β signaling in myogenesis 
In vivo experiments suggest that TGFβ prevents premature differentiation of migrating 
progenitor myoblasts, allowing sufficient proliferation of myoblasts before differentiation of 
limb muscle in the developing embryo. Large amounts of BMP2, one of the TGFβ ligands, were 
found in the limb bud along with the ectoderm. Moreover, BMP2 was shown to inhibit the 
differentiation of secondary myoblasts but not the differentiation of embryonic myoblasts 
(Yanagisawa et al., 2001). Furthermore, cell culture experiments revealed that TGFβ is a potent 
inhibitor of myoblast differentiation (Olson et al., 1986). TGFβ stimulation led to reduced cell 
fusion and reduced expression of myogenic markers, troponin T and α-actin while fibronectin 
and collagen type I was upregulated (Massagué et al., 1986). If however, TGFβ stimulation was 
removed, the cells would immediately express myogenic related genes and undergo normal 
differentiation (Massagué et al., 1986, Olson et al., 1986). It is important to note that after the 
onset of differentiation stimulation, the cells would become resistant to the antagonistic effect of 
TGFβ on myoblast differentiation (Florini et al., 1991). Interestingly, the effect TGFβ has on 
myogenesis was shown to be dependent on cell culture density. The higher the density, the larger 
the inhibitory effect of TGFβ on differentiation, and the myoblasts would undergo differentiation 
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if the cells were cultured at low density or co-cultured with non-mesenchymal cells, such as C5 
epithelial cells, even with presence of TGFβ (Zentella and Massague, 1992, De Angelis et al., 
1998). TGFβ was shown to inhibit the transcriptional activity of Myogenin and another group 
showed that upon TGFβ stimulation, MEF2C was exported out of the nucleus while the MRFs 
localized in the nucleus (Brennan et al., 1991, De Angelis et al., 1998). 
Furthermore, Smad3 alone was shown to bind to MyoD, on the HLH domain that is required for 
association with its E-protein co activators such as E12 and E47 (Liu et al., 2001). However, 
since Smad7 is not able to reverse the inhibitory effect of TGFβ on myogenesis, the complete 
intracellular mechanism by which TGFβ inhibits myogenesis has yet to be elucidated, even after 
almost four decades since the first cell culture effects were described. 
It has been suggested that TGFβ represses myogenesis through the canonical 
TGFβ/Smad3 pathway. However, there are three reasons why the canonical TGFβ/Smad3 
pathway cannot be the only intracellular mechanism for this inhibitory effect. Firstly, Smad3 
inhibition by introduction of a Smad3 specific inhibitor (SIS3) was not able to reverse the effect 
of TGFβ on myogenesis. Secondly, even though Smad7 is a potent inhibitor of Smad3 activity, 
introduction of Smad7 does not reverse the inhibitory effect of TGFβ on myogenesis (Kollias et 
al., 2006). Lastly, introduction of a MEK inhibitor reverses the inhibitory effect of TGFβ on 
myogenesis, suggesting a non-canonical pathway independent of the R-Smads (Miyake et al., 
2009). 
Role of Smad7 in myogenesis 
Our group showed that Smad7 is required for the normal course of differentiation in 
C2C12 myoblasts. siRNA mediated depletion of endogenous Smad7 led to attenuated levels of 
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MyoD, Mef2A, MyHC, and Myogenin levels, all of which increase in the normal course of 
differentiation. Smad2, -3, and -4 protein levels and Smad2, -3 phosphorylation levels were not 
affected even though exogenous Smad7 is able to repress Smad2, and -3 transcriptional activity. 
Furthermore, the ectopic expression of Smad7 was able to attenuate the inhibitory effect of 
myostatin (a member of the TGFβ ligand superfamily), but not TGFβ on myogenesis which 
means that TGFβ inhibits myogenesis through a Smad2/3 independent mechanism (Kollias et al., 
2006). 
In addition, exogenous Smad7 is not only able to reverse the inhibitory effect of 
Myostatin on myogenesis, it also enhanced expression of myogenic markers and myotube 
formation (Kollias et al., 2006). Furthermore, our group provided further evidence that 
exogenous nuclear Smad7 is sufficient for promoting myogenesis, independent of its role with 
TGFβ at the receptor level (Miyake et al., 2010). 
Cohen et al. investigated the loss of function of Smad7 in vivo by generating a Smad7 
knockout mice. Smad7(-/-) mice showed hypotrophic, underdeveloped muscle fibres, resulting in 
reduced muscle mass and force generation compared to wild-type mice. Moreover, muscle 
regeneration was delayed in Smad7(-/-) mice due to reduced satellite cell activation(Cohen et al., 
2015). 
Smad7 was shown to directly bind to, and protect MyoD from the repressive effects of 
MEK, suggesting a nuclear coactivator role for Smad7, which is independent of its antagonistic 
role on TGFβ signalling (Kollias et al., 2006). It is important to further explore Smad7’s function 
in the nucleus for intracellular mechanisms that result in the effect of Smad7 on myogenesis.  
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Epigenetic changes during skeletal muscle differentiation 
Numerous covalent modifications have been directly regulate the transcriptional state of 
genes, such as the marks H3K4me3 and H3K9Ac, which have been associated with 
decondensation of DNA, allowing physical access transcription factors and transcription of 
nearby genes, and H3K27me3 which is associated with transcriptional repression of genes in 
proximity of the histone mark (Zhang et al., 2015, Blais, 2015). 
ChIP-seq experiments comparing C2C12 myoblasts and myotubes revealed many histone 
mark changes at muscle specific transcriptional enhancers, the majority of which were MyoD 
dependent, because these histone mark changes were reduced in MyoD depleted conditions in 
myoblasts (Asp et al., 2011, Vethantham et al., 2012, Blum et al., 2012, Cheng et al., 2014). 
MyoD was shown to play an active role in forming the landscape of histone marks on enhancers 
through Setd7. Setd7 is an H3-lysine 4 specific methyltransferase and an important enzyme 
required for normal myogenesis (Tao et al., 2011). 
H3K4me1 was shown to be a transcriptionally repressive marker in the context of myogenesis as 
the reduction in this mark led to an upregulation of muscle specific genes (Cheng et al., 2014). 
At the onset of differentiation, in the normal course of myogenesis, the H3-lysine-4 specific 
demethylase, Lsd1 has been shown to remove the repressive H3K4me1 mark at muscle specific 
enhancer regions, paving the way for MLL1, a H3 methyltransferase, to trimethylate H3K4. The 
trimethylation of H3K4 cannot be reversed by Lsd1, resulting in the transcriptional activation of 
the genes examined. Interestingly, H3K4me3 is recognized by the Inhibitor of Growth 1 (ING1), 
which recruits an Lsd1/Sin3a complex that can antagonize any further H3K4me1 marks in 
proximity (Cheng et al., 2014). 
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In contrast to H3K4me3, H3K27me3 represses transcription of nearby genes. The 
catalytic subunit of Polycomb Repressive Complex 2 (PRC2), Ezh2, was shown to antagonize 
muscle gene induction, and as a result, inhibit myogenic differentiation (Caretti et al., 2004). The 
transcription factor Yy1 was shown to recruit Ezh2 to muscle specific genes to induce H3K27 
trimethylation before differentiation. However, Ezh2 and Yy1 are removed from the muscle 
specific genes at the onset of differentiation, resulting in lower levels of H3K27me3 and 
transcriptional activation of the genes (Lu et al., 2013). 
Furthermore, the enzyme Lysine Demethylase 6A (KDM6A) was shown to be recruited by the 
histone chaperone Spt6 and demethylate H3K27 (Wang et al., 2013). Spt6 is also reported to 
assist passage of RNA pol II through destabilization of nucleosomes. Knockdown of Spt6 results 
in increased levels of H3K27me3, reduced expression of muscle specific genes, and inhibition of 
myogenesis (Seenundun et al., 2010). 
 
 
 
 
 
 
 
 
 
26 
 
Statement of Purpose 
Our group previously showed that introduction of exogenous Smad7 in C2C12 cells induced 
early myogenesis by amplifying expression of MRFs. Smad7 was shown to cooperate with -and 
promote- MyoD driven myogenesis (Kollias et al., 2006). A follow up study revealed exogenous 
nuclear Smad7 had the capacity to induce an equivalent effect on myogenesis, ruling out 
Smad7’s well characterized cytoplasmic role as the main underlying mechanism for the observed 
effects (Miyake et al., 2010). 
A recent screen for Smad7 interacting proteins indicated an interaction between Smad7 and 
SET/TAF-Iβ, a nuclear localized proto-oncogene which plays diverse functions in chromatin 
remodeling, cell cycle, autophagy, and apoptosis. SET is a major subunit of the INHAT 
(Inhibitor of Histone Acetylation) complex capable of binding to – and masking – histones from 
acetylation, particularly H3 and H4 tails, resulting transcriptional inhibition of nearby genes.  
We speculated that SET may play a major role in the epigenetic changes required for myogenesis 
by functioning as a transcriptional inhibitor of muscle specific genes. We hypothesized that 
Smad7 antagonizes this repressive effect of SET on muscle specific genes, resulting in early 
myogenesis. 
Exploring the role of SET and Smad7 interaction in skeletal myogenesis is pivotal to our 
understanding of skeletal muscle ontogeny and physiology. 
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Introduction 
Skeletal muscle is an essential tissue that allows locomotion and supports proper posture 
for vertebrates. Skeletal muscle differentiation (myogenesis) is the process of converting mono-
nucleated myoblasts into multi-nucleated myotubes that form the basis of musculature. 
Myogenesis requires a highly coordinated program of gene expression that involves MRF and 
MEF2 transcription factors as major orchestrators inducing muscle specific gene expression. The 
TGFβ signaling pathway plays an essential role in myogenesis, inhibiting premature 
differentiation of myoblasts to ensure sufficient number of myoblasts are present before fusion 
and differentiation into myotubes. A major inhibitor of the canonical TGFβ signaling pathway is 
Smad7 which binds to the activated TGFβ receptor complex and inhibits downstream signaling. 
Interestingly, exogenous wildtype Smad7 does not reverse the inhibitory effect of TGFβ on 
myogenesis indicating a different, non-canonical downstream signaling pathway as the 
underlying mechanism.  
Our group recently showed that exogenous nuclear Smad7 is capable of inducing 
premature myoblast differentiation, indicating a noncanonical role for Smad7 in myogenesis. 
Smad7 was shown to form a mutually reinforcing positive feedback loop with MyoD, with 
Smad7 protecting MyoD transcription activity from the repressive effects of Mek, and MyoD 
promoting Smad7 expression. However, further elucidation of the nuclear role of Smad7 is 
needed, especially how Smad7 activity is regulated in the nucleus. A recent screen for Smad7 
interacting partners indicated an interaction between Smad7 and SET/TAF-Iβ, a nuclear proto-
oncogene involved in diverse functions such as chromatin remodeling, histone masking, and cell 
cycle (unpublished data).  
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Here we show that SET is capable of inducing epigenetic changes leading to 
transcriptional repression of myogenic related genes such as mck and myogenin, and ‘anti’-
myogenesis genes such as cyclin D1. We show that Smad7 is able to bind to, and antagonize 
SET’s repressive effect on myogenic related genes, but not cyclin D1. SET mediated repression 
of the cell cycle coupled with Smad7’s antagonism of SET at myogenic genes results in a 
pronounced enhancement of myogenesis compared to Smad7 enhancement alone. 
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Materials and Methods 
Plasmids 
WT-myc-Smad7 and myc-Smad7-NLS expression vectors were described previously (Miyake et 
al., 2010, Kollias et al., 2006). Luciferase reporter constructs, pMCK-luc (Donoviel et al., 1996) 
and pMyoG-luc (Miyake et al., 2010) were described elsewhere. Flag-SET expression vector 
(#24998) was purchased from Addgene. 
Antibodies 
Mouse IgG (sc-2025), dsRed (sc-33354), MCK (sc-365046), Actin (sc-1616) antibodies were 
purchased from Santa Cruz Biotechnology. FLAG(A-9594) antibody was purchased from Sigma. 
H3K9ac(ab4441), H3(ab1791), H3K4me3(ab8580), H3K27me3(ab6002) antibodies were 
purchased from Abcam. Myogenin (F5D), Myc (9E10), and MyHC (MF20) antibodies were 
from Dako Cytomation. Rabbit IgG (12-370) was from Millipore. 
Cell Culture 
C2C12 and HEK293T cells were purchased from American Type Culture Collection. The cells 
were all cultured in 10% Fetal bovine serum (FBS) (HyClone) in high-glucose Dulbecco’s 
modified Eagle’s medium (DMEM) (Hyclone) with 1% penicillin-streptomycin (Invitrogen) at 
5% CO2 and at 37°C. The differentiation conditions were in 2% horse serum (Atlanta 
Biologicals) in high glucose DMEM supplemented with 1% penicillin-streptomycin (Invitrogen). 
Western blotting analysis 
Conventional cell scrapers were used to collect cells in 1X cold PBS. NP-40 lysis buffer (0.1 % 
NP-40, 150 mM NaCl, 1mM EDTA, 50 mM Tris-HCl pH 8.0, 1mM sodium vanadate, 1mM 
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PMSF, supplemented with a protease inhibitor cocktail (Sigma, P-8340)) was used for 
biochemical lysis. Standard Bradford assay was used to determine protein concentrations 
(BioRad). Equal amounts of proteins were loaded on 10% SDS-PAGE gels and subsequent 
electrophoretic transfer was done on Immobilon-P membranes (Millipore). Blocking was done 
for 1hr in 5% milk in PBS, primary antibody was in 2% milk in PBS or Tris buffered saline 
(TBS)-T (10mM Tris-HCl pH8.0, 150mM NaCl, 0.1% Tween-20) incubated at 4°C overnight. 
HRP-conjugated secondary antibodies in 5% milk in PBS were incubated at room temperature 
for 1 hour (Santa Cruz Biotechnology, Cell Signaling Technology). Enhanced 
chemiluminescence reagent (Amersham) was used to detect immuno-reactive secondary 
antibodies still bound to the membrane. The membranes were then exposed to Biomax film 
(Kodak). All washes were done with 1X PBS. 
Co-Immunoprecipitation assay 
An equal amount of total cellular protein (250μg) was diluted with NP-40 lysis buffer to a final 
concentration of 1 μg/μl. Protein complexes were immunoprecipitated with the indicated 
antibody and 25μl of protein GPlus Sepharose beads (50% slurry) (Santa Cruz Biotechnology) 
by incubation at 4°C overnight on a rotating platform. The beads were washed three times with 
the following wash buffer (0.1% NP-40, 150mM NaCl, 1mM EDTA, and 50 mM Tris-HCl pH 
8.0). Beads were boiled in SDS sample buffer, and protein complexes were resolved by SDS-
PAGE and immuno-blotted as described above. 
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Reverse Transcription 
Total RNA was extracted from cells using the RNeasy Plus kit (Qiagen) and Qiashredder 
(Qiagen). RNA was converted to cDNA using Superscript III (Invitrogen) according to the 
manufacturer’s instructions. 
Quantitative PCR 
SybrGreen (BioRad) was combined with 2.5 μl cDNA and 500 nM primers in a final volume of 
20 μl. cDNA was diluted 1:10 prior to use. Each sample was prepared in triplicate and analyzed 
using Rotor-Gene Q (Qiagen). Parameters for qRT-PCR using BioRad: 30s 95°C, [5s 95°C, 30s 
60°C] x 40 cycles. Parameters for ChIP-qPCR: 5min 95°C, [5s 95°C, 15s 60°C] x 40 cycles. 
Fold change (qRT-PCR) was quantified using the ∆∆Ct method. Primers used in ChIP-qPCR and 
qRT-PCR are listed in Supplementary Table S1 and S2. 
Chomatin Immunoprecipitation 
Methods were carried out as described previously, however a third IP Wash Buffer was added 
(IP Wash Buffer III; 20 mM Tris pH 8.1, 250 mM LiCl, 1% NP-40, 1% deoxycholate, 1 mM 
EDTA). See Supplementary Table S2 for primers used in ChIP. 
MyHC Staining 
C2C12 cells were washed with Phosphate buffered saline (PBS) (pH7.4) and fixed with 4°C 
paraformaldehyde (4%) for 10min at room temperature followed by membrane permeabilization 
by 90% methanol at 4°C for 10 min. The cells were blocked using 5% milk in PBS for 1 hour at 
37 °C. Cells were incubated at room temperature with MF-20 (MyHC antibody) diluted in 
blocking buffer (2% milk PBS) for 1 hour. Cells were then washed three times with PBS and 
incubated for 60 min at room temperature with Horseradish peroxidase (HRP)-conjugated α-
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mouse secondary antibody. The cells were washed three times with PBS and incubated in 
developer (0.6 mg/ml DAB, 0.1 % H2O2 in PBS) to detect MyHC by immunocytochemistry. 
Images were recorded with a microscope (Axiovert 35; Carl Zeiss MicroImaging) with 10X NA 
0.25 Achrostigmat objective lenses with the Canon EOS D60 digital camera. 
Quantification of Western Blots  
Quantification of the western blots were carried out using ImageJ (1.8.0_77) analysis software 
following instructions described previously (Davarinejad, 2015). 
Transfections 
All transfections were carried out using conventional CaPO4 transfection method (see extended 
MM for protocol). 
Luciferase Assay 
Cells were transfected via the CaPO4 transfection protocol, followed by 24h recovery in 10% 
FBS DMEM. The cells were then washed with 1X cold PBS and were lysed using the luciferase 
lysis buffer (see Extended MM for buffer recipe). Aliquots were taken for each of the three 
replicates and luciferase activity was analysed using Lumat3 Berthold Technologies (LB 9508) 
per manufacturer’s instructions. Luciferase substrate was purchased from Promega (E151A). 
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Results 
Exogenous SET and Smad7 form a complex 
To confirm the interaction between SET and Smad7, exogenous Flag-SET and myc-
Smad7 were expressed in human embryonic kidney HEK293T cells. The cell lysate was 
subjected to immuno-precipitation analysis. Figure 8B shows presence of exogenous myc-
Smad7 in the Flag-SET immuno-precipitate but not by normal IgG. Figure 8C indicates 
presence of Flag- in the myc-Smad7 immuno-precipitate but not the corresponding control IgG. 
The results here show an interaction between exogenously expressed SET and Smad7 in 
HEK293T cells. 
Figure 8: Exogenous SET and Smad7 interact in HEK293T cells. A: Cells were lysed 
biochemically (NP-40) and incubated with agarose beads conjugated with either Flag or Myc 
antibodies overnight at 4°C, followed by Western blot analysis. Mouse or Rabbit IgG was used 
as control for specificity of Smad7 and SET respectively. A: Diagram showing summary of 
experimental design. B: Blots showing successfully immunoprecipitated Flag-SET (top blot) and 
presence of myc-Smad7 in the immunoprecipitated complex (bottom blot) C: Blots showing 
successfully immunoprecipitated myc-Smad7 (top blot) and presence of Flag-SET in the 
immunoprecipitated complex (bottom blot).  
34 
 
Exogenous SET-Smad7 interaction induces premature differentiation 
 To investigate possible effects the SET-Smad7 interaction may have on myogenesis, 
exogenous SET and/or Smad7 were expressed in C2C12 cells, left to differentiate in low serum 
conditions for 72H, followed by immunostaining for MyHC to compare levels of myotube 
formation. Figure 9C shows a higher level of myotube formation when exogenous Smad7-NLS 
is expressed (bottom left) compared to pcDNA control, as reported previously (Kollias et al., 
2006, Miyake et al., 2010). In contrast, exogenous SET expression induces cell-death indicated 
by floating round cells along with minimum myotube formation throughout the cultured dish 
(Top right). However, co-expression of SET and Smad7-NLS leads to an enhancement of 
myotube formation, with more robust myotubes formed compared to exogenous Smad7 alone. 
These results indicate that while SET alone inhibits myogenesis, when introduced with Smad7 
together, leads to promotion of myogenesis and myotube formation, even more so than 
exogenous Smad7 alone. Figure 9B shows immunoblots of lysates from similarly transfected 
cells, indicating expression levels of myc-Smad7 and Flag-SET. 
To examine whether the effects seen are due to deprivation of Smad7 from the cytoplasm, the 
experiment was repeated with wildtype-Smad7 with similar end results, shown in 
Supplementary Figure 1. 
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Figure 9: Exogenous SET and Smad7 promote myogenesis while ectopic expression of SET 
alone leads to cell death. C2C12 cells were transfected with Flag-Set and/or Smad7, left to 
differentiate for 72H in low serum conditions (2% HS) followed by 4% paraformaldehyde 
fixation and immunostaining MyHC. A: Diagram showing summary of experimental design. B: 
Western blot analysis using lysates of similarly transfected cells C: MyHC staining showing 
level of myotube formation.  
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Exogenous SET and Smad7 induce early expression of myogenic markers  
To further investigate this phenotype induced by the SET and Smad7 interaction at a 
molecular level, exogenous SET and Smad7 were expressed in C2C12 cells and followed by 
Western blot analysis of myogenic markers in a differentiation timecourse. The resulting 
Immunoblots shown in Figure 10 indicate a delayed MCK and MyoG expression with presence 
of exogenous Flag-SET. In-line with the previously reported data, expression of exogenous myc-
Smad7 induced early MCK and MyoG expression when compared to control (Miyake et al., 
2010, Kollias et al., 2006). However, co-expression of Flag-SET and myc-Smad7 led to an early 
amplification of MCK and MyoG expression, even more so than myc-Smad7 alone. Although 
exogenous Flag-SET alone repressed myogenic marker expression, exogenous co-expression of 
Smad7 and SET enhanced MCK and MyoG.  
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Figure 10: C2C12 differentiation timecourse with exogenous Smad7 and SET. C2C12 cells 
transfected with Smad7 and/or SET, left to recover in 10% FBS DMEM for 24H before 
biochemical lysis (NP-40) followed by Western Blot analysis. A: Diagram showing summary of 
experimental design. B: Western blots showing expression levels of the myogenic markers at 
various time points. 
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SET and Smad7 increase MCK and MyoG promoter activity    
We decided to further investigate the promoter activity of the muscle marker genes in the 
presence of exogenous SET and/or Smad7 using luciferase reporter assays in C2C12 cells, 
shown in Figure 11C. Exogenous SET expression reduced mck promoter activity compared to 
that of control and while exogenous Smad7 enhanced the same promoter by ~3 fold, co-
expression of exogenous SET and Smad7 together resulted in a near 5 fold increase in promoter 
activity within 24H after transfection. The myog promoter responded similarly to the mck 
promoter, with exception of when exogenous SET was expressed alone. The results here show an 
increase in the activity of both mck and myog promoter when exogenous SET and Smad7 are co-
expressed.  
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Figure 11: Luciferase assays of MyoG and MCK in the presence of exogenous SET and/or 
Smad7. SET and/or Smad7 were transfected into C2C12 cells along with either MCK (Left) or 
MyoG (Right) promoters fused to a luciferase reporter gene. A: Diagram showing summary of 
experimental design. B: Western blot showing expression levels of exogenous SET and Smad7. 
C: Results of the luciferase assay, with MCK-Luc (Left) or MyoG-Luc (right). Error bars 
represent SD values. 
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Endogenous mRNA levels of SET and Smad7 in a timecourse of C2C12 
differentiation 
To examine whether SET and Smad7 expression is changed during the C2C12 
differentiation, we isolated total RNA from untransfected C2C12 cells in a timecourse, followed 
by RT-qPCR analysis shown in Figure 12. The results indicate peak endogenous Smad7 mRNA 
expression at the 24 hour timepoint, lowering after 72 hours in low serum. Interestingly, SET 
mRNA levels decrease throughout the differentiation process. The results here along with 
previous data indicate that reduction of SET expression is suitable for muscle differentiation. 
MCK and MyHC are expressed in later stages of differentiation at 72H, while Myogenin 
expression increases with time.   
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Figure 12: Endogenous mRNA levels of SET and Smad7 in a C2C12 differentiation 
timecourse. C2C12 cells were cultured in 10% FBS DMEM and switched to 2% HS DMEM for 
the stated duration once reaching confluency. Total RNA was then isolated using manufacturer’s 
instructions (Qiagen) followed by standard RT-qPCR analysis. A: Diagram showing summary of 
experimental design. B: Results for qPCR reaction using primers against stated genes. Error Bars 
represent SD values.  
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Exogenous SET and Smad7 enhance myogenic marker expression at the 
promoter level  
To confirm SET and Smad7 modulation of myogenic markers at mRNA level, exogenous 
SET and Smad7 were expressed in C2C12 cells, and mRNA levels of myogenic markers were 
quantified at various timepoints using RT-qPCR. The results shown in Figure 13, indicate an 
increase in mRNA levels of MCK, MyHC, and MyoG when exogenous Smad7 is present. In 
contrast, mRNA levels of all three markers decrease with expression of exogenous SET. 
However, exogenous expression of both SET and Smad7 resulted in a large increase in mRNA 
levels of the three myogenic markers analysed, showing a greater effect than that of exogenous 
Smad7 alone. 
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Figure 13: Myogenic marker mRNA levels in a C2C12 differentiation timecourse in the 
presence of exogenous SET and/or Smad7. C2C12 cells were transfected with SET and/or 
Smad7 and left to differentiate in 2% horse serum for the indicated hours before total RNA 
isolation and subsequent RT-qPCR analysis. A: Diagram showing summary of experimental 
design. B: Western blot analysis from lysates extracted from similarly transfected cells. C: RT-
qPCR analysis shows mRNA levels of genes shown. Error Bars represent SD values. 
 
Exogenous SET and Smad7 can alter total histone acetylation/methylation 
levels  
SET is a major subunit of the INHAT complex capable of masking histone tails from 
acetylation. To investigate possible epigenetic modulations resulting from expression of 
exogenous SET and Smad7, we immunoblotted total cell lysates using antibodies specific to 
histone markers. 
Figure 14 shows Exogenous SET expression induced large decreases in overall levels of 
both transcription activating marks (H3K4me3 and H3K9Ac), and a large increase in the 
transcription repressive mark H3K27me3 throughout the three timepoints when compared to the 
control pcDNA. In contrast, exogenous Smad7 induced an increase in levels of both activating 
marks H3K4me3 and H3K9Ac, and a small decrease in levels of repressive mark H3K27me3 
when compared to control. Interestingly, when exogenous SET and Smad7 were co-expressed, 
there was a significant increase in total levels of activating marks H3K4me3 and H3K9Ac, and a 
significant decrease in levels of the repressive mark H3K27me3 when compared to pcDNA 
control, even more so than the effect of exogenous Smad7 alone. 
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Figure 14: Modulation of total levels of histone marks H3K4me3, H3K9Ac, and H3K27me3 
in the presence of exogenous SET and/or Smad7 in a C2C12 differentiation timecourse. 
C2C12 cells were transfected with either SET, Smad7, or SET+Smad7 and left to differentiate in 
2% horse serum for the indicated hours. Western blots were carried out, loading total lysate and 
using antibodies against the indicated histone marks. H3K4me3 and K9Act are known to 
generally activate gene transcription, while K27me3 represses gene transcription. A: Diagram 
showing summary of experimental design B: Immunoblots of the histone marks. Quantification 
of the western blots are shown in Supplementary Figure 2. 
Smad7 inhibits the histone masking abilities of SET 
To explore the interplay between SET, Smad7, and histone marks in the context of 
myogenesis, ChIP experiments were performed using histone mark specific antibodies with 
C2C12 cell lysates transfected with SET and/or Smad7 followed by a subsequent qPCR analysis 
of regions of interest. As shown in Figure 15, this experiment was designed with 4 different 
conditions: transfected pcDNA construct serving as control, transfected SET or Smad7 
constructs alone, or transfected SET and Smad7 constructs together. Using antibodies specific to 
the histone marks, we analysed levels of the histone marks in the regions of interest shown in 
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Figure 15. H3K4me3 and H3K9Ac marks are known to be a transcription activating mark, while 
the H3K27me3 mark is generally a transcription repressive mark.  
Exogenous expression of SET alone resulted in decreased levels of the H3K4me3 and 
H3K9Ac marks in proximity of the regulatory regions of all the genes examined with the 
exception of gapdh. This corresponds with previously reported literature of SET’s histone 
masking properties. However, expression of exogenous SET also led to increased H3K27me3 
levels in all the genes with the exception of gapdh. The constitutively active expression level of 
the gapdh gene requires maintenance of a constant ‘open’ DNA template state that does not 
include nucleosomes or histone proteins in proximity of its regulatory regions. This may explain 
why the epigenetic changes seen with introduction of exogenous SET does not apply to the 
gapdh gene. Overall, the results here suggest that SET functions as a transcriptional repressor for 
the mck, myogenin, and cyclin D1 genes by inhibiting transcription activating marks such as the 
H3K4me3 and H3K9Ac and promoting H3K27me3 marks around the regulatory regions of those 
genes. However, due to the open DNA template state of gapdh, SET is not able to modulate 
GAPDH expression levels. 
In contrast to the effects of SET, exogenous Smad7 induced lower levels of the repressive 
mark (H3K27me3), and higher levels of activating marks (H3K4me3 & H3K9Ac) on the 
regulatory regions of myogenic related genes examined. Smad7 is therefore a transcriptional 
activator to mck and myogenin, but has no effect on the epigenetic marks near the regulatory 
regions of either cyclin D1 or gapdh genes.  
The introduction of exogenous SET and Smad7 together resulted in higher levels of 
activating marks (H3K4me3/H3K9Ac) lower levels of the repressive mark (H3K27me3) in the 
regulatory regions of both mck and myogenin when compared to that of expression of exogenous 
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Smad7 alone. This result corresponds to the increased expression of the mck and myogenin genes 
shown in Figure 13 and the increased MCK and MyoG protein levels shown in Figure 10. 
Interestingly, SET’s repressing role on the cyclin D1 promoter is not effected when 
introduced together with exogenous Smad7. Unlike the Smad7 antagonizing effect of SET on the 
mck and myogenin genes, similar levels of both activating, and repressing histone marks are seen 
on the cyclin D1 promoter regardless of the presence of exogenous Smad7. This suggests that 
Smad7 is able to target and inhibit SET’s repressive effect on histones near regulatory regions of 
myogenic related genes but Smad7 does not modulate SET’s repressive activity on the cyclin D1 
promoter.  
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Figure 15: Epigenetic changes to the regulatory regions of mck, myogenin, cyclin D1, and 
gapdh in the presence of exogenous SET and/or Smad7. C2C12 cells were transfected with 
the stated constructs, left to recover for 24H in 10% FBS DMEM before crosslinking (4% 
paraformaldehyde), sonication, and ChIP with specified antibodies followed by qPCR using 
primers designed for regulatory regions of the genes (primer designs shown in Supplementary 
Figure 3). Rabbit IgG was used as ChIP control for the H3K4me3 and H3K27me3 antibodies 
while Mouse IgG was used as control for the H3K9Ac antibody. A: The Percent Input method 
was used to quantify the results displayed in the graph. Error bars represent SD values. B: 
Diagram showing summary of experimental design. C: Western blot analysis of total lysates 
from similarly transfected cells. 
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Discussion 
Previous work from our group showed that exogenous Smad7 is able to promote 
myogenesis, leading to the upregulation of myogenic markers Myogenin, MCK, and MyHC. 
Although Smad7 is viewed as a potent inhibitor of the canonical TGFβ/Smad3 pathway, it was 
unable to reverse TGFβ’s inhibitory effect on myogenesis, suggesting a different role for Smad7 
in myogenic cells.  Smad7 was shown to physically interact with, and enhance MyoD’s 
transcriptional properties (Kollias et al., 2006). A follow up study from our group revealed that 
nuclear Smad7 was able to promote myotube formation and upregulate myogenic markers even 
though Smad3 activity remained unchanged (Miyake et al., 2010). This further confirms the 
hypothesis that Smad7 promotes myogenesis via its nuclear role since depriving Smad7 of its 
cytoplasmic function did not reverse its effect on myogenesis. However, many questions remain 
unanswered about the regulation of Smad7 within the nucleus in contrast to the extensive 
research done on Smad7’s cytoplasmic role. It is therefore essential to elucidate how Smad7’s 
nuclear function is regulated within skeletal muscle, as its enhancement of myogenesis could 
have significant therapeutic potential.  
A recent screen for Smad7 interacting proteins indicated an interaction between Smad7 
and SET/TAF-Iβ, a nuclear proto-oncogene that is mainly known for its masking abilities of 
histone tails. SET, also known as 2PP2α/IGAAD/TAF-I/I2PP2α/IPP2α2/PHAPII/TAF-Iβ, is a 
member of the Nuclear Assembly Protein 1 (NAP1) family (Park and Luger, 2006). SET was 
initially identified as the product of a gene that was fused to the can gene as a result of a 
translocation in a patient with acute undifferentiated leukemia (Von Lindern et al., 1992). Along 
with its histone chaperone properties, SET is a major subunit of the INHAT complex that masks 
histone proteins from modifications, i.e. P300 acetylation, by binding to the histone tails of 
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H3/H4 and blocking physical access of HATs, a mechanism referred to as ‘histone masking’ 
(Seo et al., 2001, Muto et al., 2007). SET was reported to stimulate transcription in an in vitro 
model adenovirus system by promoting structural changes around promoter regions by 
disrupting and remodeling the Ad core, making transcription and replication apparatus accessible 
to template DNA. A C-terminally truncated SET construct was completely inactive in this 
function, suggesting that the acidic C-terminus is required to stimulate transcription on 
chromatin (Matsumoto et al., 1999, Okuwaki and Nagata, 1998). 
Many studies have revealed the involvement of SET in promoter specific transcription 
regulation. Using two-step ChIP experiments, Telese et. al. show that SET forms a complex with 
the transcription factors Fe65, AICD, and Tip60 on the promoter region of the KAI1 gene 
involved in cell adhesion. siRNA-mediated depletion of SET resulted in lower mRNA levels of 
KAI (Telese et al., 2005). Furthermore, Compagnone et al. show that SET (reported as StF-IT-1) 
forms a complex with the transcription factors COUP-TF, NGF-IB, and SF-1 on the P450c17 
gene which produces the crucial enzyme for synthesis of DHEA in the brain. The authors also 
report that SET’s developmental pattern of expression suggests it may participate in early 
ontogenesis of the nervous system, as well as the skeletal and hematopoietic systems 
(Compagnone et al., 2000). Kim et al.  showed that SET is recruited to the promoter of the atf3 
gene, a member of CREB protein family of transcription factors. SET was shown to recognize 
and bind to PRC2-mediated H3K27me3 mark around the atf3 promoter, further helping to 
repress the transcription of the atf3 gene(Kim et al., 2012). 
Ichijo et al. show that SET co-precipitated with glucocorticoid response elements (GREs) on the 
promoters of glucocorticoid receptor target genes in the absence of Dexamethasone. The DNA 
binding domain of the activated Glucocorticoid receptor was shown to bind to, and release SET 
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from glucocorticoid-responsive gene promotes, relieving transcriptional repression. Interestingly, 
the product of the fused set-can gene does not retain the same physiologic responsiveness to 
ligand bound GR, possibly contributing to the poor responsiveness of set-can-harboring 
leukemic cells to glucocorticoids(Ichijo et al., 2008).  
Kim et al. reported that SET negatively regulates neuronal cell differentiation. The 
authors show that SET is expressed abundantly in neuronal tissues of Drosophila embryos 
during neuronal development, gradually reducing as differentiation proceeds. SET was shown to 
bind to the promoters of a subset of neuronal development markers, repressing the transcription 
of these genes by inhibiting acetylation of H4. siRNA mediated depletion of SET resulted in 
enhancement of neuronal cell differentiation, implicating SET as a negative regulator of neuronal 
development by targeting and ‘histone masking’ the promoters of the neuronal development 
markers(Kim et al., 2010). 
SET was also shown to bind to, and repress p21 activity, a repressor of Cyclin B-CDK1, 
allowing cell cycle progression from G2 Phase into M phase (Canela et al., 2003). SET is also a 
potent inhibitor of Protein Phosphatase 2A (PP2A) as RNAi-mediated SET depletion resulted in 
increased activity and expression of PP2A and its target gene MMP-9 (Li et al., 1996). 
Moreover, SET also plays a role in Granzyme A-mediated apoptosis as it was shown to form a 
complex with, and regulate the activity of APE-1, a base excision repair endonuclease 
responsible for DNA repair (Fan et al., 2003). 
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Figure 16: Comparison of the structure and functional domains of SET and NAP1. The 
NAP domain is required for histone protein binding while the highly acidic C terminal 
domain is required for binding and forming the INHAT complex. 
The schematic diagram in Figure 16 shows the structure and functional domains of SET. 
The NAP domain is highly conserved in all NAP1 family proteins and is required for histone 
protein binding. The highly acidic C-terminal domain of SET is highly disordered in structure 
and although it’s not required for histone protein binding, it is a necessity for binding to and 
forming the INHAT complex. The SET protein exists as a dimer, forming a ‘headphone’ shape. 
The focus of this study was the histone masking abilities of SET and its interaction with 
Smad7 in the context of myogenesis. The histone tail modifications on muscle specific genes are 
vital for the execution of the differentiation program since most transcription factors function on 
a chromatin template that depends on these modifications. Numerous covalent modifications that 
have been directly linked to regulating the transcriptional state of genes, such as H3K4me3 and 
H3K9Ac which have been associated with enhancing transcription, and H3K27me3 which is 
majorly reported to repress transcription of genes in proximity (Zhang et al., 2015). 
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Here we showed that the ectopic expression of SET resulted in an increase in total 
H3K27me3 levels in the cell lysates. Moreover, both promoters of myog, and mck, along with the 
upstream enhancer region of myog displayed increased levels of the H3K27me3 mark, resulting 
in lower myogenic markers at both the mRNA and protein level and inhibition of myogenesis. 
Ectopic expression of SET also resulted in increased levels of H3K27me3 mark at the promoter 
region of cyclin D1 but no change in H3K27me3 levels was seen on the regulatory region of the 
housekeeping gene gapdh. 
Although exogenous Smad7 alone did not display any change in the levels of H3K27me3, when 
introduced together with exogenous SET, Smad7 was able to not only reverse the effect of SET, 
it also led to a decrease in H3K27me3 levels compared to control. The lower levels of 
H3K27me3 corresponded with increased expression of MyoG and MCK at both the mRNA, and 
protein level. Ectopic expression of Smad7 alone did not change H3K27me3 levels on either 
cyclin D1 or gapdh promoters. (Figure 17) 
Ectopic expression of SET alone reduced levels of both transcription activating marks H3K4me3 
and H3K9Ac on mck and myog promoters along with the cyclin D1 promoter compared to 
control. In contrast, exogenous Smad7 alone was able to marginally increase H3K4me3 and 
H3K9ac levels on mck and myog promoters, but not on cyclin D1 or gapdh. (Figure 17) 
Remarkably, co-expression of exogenous SET and Smad7 led to higher levels of the 
transcriptionally activating marks H3K4me3 and H3K9Ac and lower H3K27me3 levels of the 
transcriptionally repressive mark on the mck and myog promoters than that of Smad7 alone. The 
introduction of SET and Smad7 resulted in a reversal of SET’s repressing effect on the myogenic 
promoters, while at the same time, when introduced together with Smad7, SET was able to 
enhance Smad7’s effect on activating the transcription of the myog and mck genes. The increase 
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in H3K4me3 and H3K9ac levels at the regulatory region of the mck and myog genes 
corresponded with increased expression at both the mRNA, and protein level. However, Smad7 
was unable to modulate SET’s repressive effects on the cyclin D1 promoter when both 
exogenous Smad7 and SET are introduced, suggesting that Smad7 might only target SET at the 
regulatory regions of myogenic related genes. SET and Smad7 had no effect on the 
transcriptional activity of the gapdh promoter, even when introduced together. This could be due 
to absence of nucleosomes in proximity of the promoter of gapdh since it’s always transcribed at 
constant high levels. (Figure 17) 
 
Figure 17: Schematic diagram summarizing the effects of exogenous SET and Smad7 to the 
histone marks around the regulatory regions of mck, myogenin, cyclin D1, and gapdh genes 
in the presence of exogenous SET and/or Smad7. 
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SET demonstrates an overall repressive effect on myogenesis by masking the histone 3 tail and 
preventing any transcriptionally activating modification on lysine residues K4 and K9, and SET 
concurrently promotes the repressive histone marker H3K27me3 at both the regulatory regions 
of myog and mck. This results in an inhibition of myotube formation and skeletal muscle 
differentiation. SET can therefore be seen as an antagonist of transcription of myogenic markers. 
Here we show that Smad7’s nuclear role displays contrasting effects to that of SET in the 
context of skeletal muscle differentiation. Ectopic expression of Smad7 resulted in an increase in 
transcriptionally activating histone marks and a decrease in repressive marks around the 
regulatory regions of myogenic marker genes mck and myog leading to an enhancement of 
myotube formatio. Smad7 can therefore be seen as an agonist of transcription of myogenic 
markers and myogenesis. (Figure 18) 
Surprisingly, ectopic expression of the antagonist SET and the agonist Smad7 together 
leads to an enhancement in myotube formation and an enrichment of the effects seen with 
exogenous Smad7 alone in terms of the upregulation of myogenic marker expression and the 
enhancement of myotube formation. This suggests that SET and Smad7 promote myogenesis 
when introduced together, even though SET is an antagonist of myogenesis when introduced 
alone. (Figure 18) 
One plausible explanation is that Smad7 targets and inhibits the transcriptionally 
repressive effects of SET only in the regulatory regions of myogenic related genes, while at the 
same time, the surplus levels of the SET protein lead to further repression of non-myogenic 
related genes, possibly repressing anti-myogenic genes like the cyclin D1 gene.  
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Our group previously reported that nuclear Smad7 is able to promote myogenesis by 
physically binding and enhancing MyoD’s transcriptional activity which resulted in the 
upregulation of MyoG, MCK and MHC (Kollias et al., 2006). Smad7 could potentially form a 
complex with a number of different transcription factors including MyoD, and Smad7 could be 
recruited to SET at the regulatory regions of myogenic markers through MyoD (Figure 18). SET 
mediated repression of the cell cycle coupled with Smad7’s antagonism of SET at myogenic 
genes results in a pronounced enhancement of myogenesis. 
Figure 18: Epigenetic changes to muscle specific genes and the cyclin D1 gene when 
introducing ectopic SET and Smad7. 
Summary and Future Direction 
 The results here show a transcriptional repressive role for SET in the context of 
myogenesis. SET was shown to induce epigenetic changes that result in transcriptional 
repression of myogenic related genes such as mck and myogenin as well as the cell cycle gene 
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cyclin D1. Smad7 interaction with SET near promoters of myogenic related genes leads to 
epigenetic changes that induce expression of those myogenic related genes. However, Smad7 has 
no effect on the transcriptional repressor role of SET on cyclin D1. SET mediated repression of 
the cell cycle coupled with Smad7’s antagonism of SET at myogenic genes results in a 
pronounced enhancement of myogenesis. 
 The data here showcase a novel role for SET in the context of myogenesis as well as 
revealing alternative functions of Smad7 in the molecular control of myogenesis. This highlights 
the potential therapeutic use of Smad7 and SET to offset muscle wasting in a variety of muscle 
disorders. Future work would revolve around elucidation of the underlying mechanism in which 
Smad7 targets and antagonizes SET’s repressive role on myogenic related genes but not cell 
cycle related genes such as cyclin D1. Performing ChIP-Seq analysis using histone mark specific 
antibodies on cell lysates with exogenous SET and Smad7 would provide a comprehensive 
overview of epigenetic changes when exogenous SET and Smad7 are present. This gives better 
understanding of the group of genes targeted for repression by SET and whether those genes are 
relieved from SET repression by Smad7. 
To show direct recruitment of SET and Smad7 on the promoters affected, performing a 
two-step ChIP-Seq analysis using SET or Smad7 specific antibodies on cell lysates with 
exogenous SET and Smad7. However, there are currently no antibodies that can detect 
endogenous SET or Smad7 and attempts at using ChIP grade antibodies against tags of either 
exogenous protein have not been successful. Furthermore, it would be interesting to see how 
RNAi mediated depletion of endogenous SET would impact skeletal muscle differentiation given 
its importance in epigenetic control.  
60 
 
SET may have a major role in the changes to the epigenetic landscape that are essential for 
proper myogenesis to take place. More importantly, SET may play a major role in prenatal 
skeletal muscle formation and differentiation. SET may also be involved in satellite cell 
proliferation and differentiation postnatally. There are numerous studies that target SET as a 
therapeutic strategy for cancer (Farrell et al., 2014, Janghorban et al., 2014, Sobral et al., 2014, 
Mukhopadhyay et al., 2013). SET accumulation has been reported to exacerbate prostate, breast 
and pancreatic cancers and is being currently researched as a pharmaceutical target for cancer 
therapy. Here we have shown the in vitro role of SET in myogenesis and if SET plays a similar 
role in satellite cell proliferation and differentiation, it could serve as a potential therapeutic 
target for muscle regeneration and dystrophy. 
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Supplementary Figures 
 
Supplementary Figure 1: Exogenous SET and Smad7 promote myogenesis while ectopic 
expression of SET alone leads to cell death. C2C12 cells were transfected with Flag-Set and/or 
Smad7, left to differentiate for 72H in low serum conditions (2% HS) followed by 4% 
paraformaldehyde fixation and immunostaining MyHC. A: Diagram showing summary of 
experimental design. B: Western blot analysis using lysates of similarly transfected cells C: 
MyHC staining showing level of myotube formation. 
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Supplementary Figure 2: Quantification of Western blots shown in Figure 14. 
Quantification ratio is the Mean Grey Value (MGV) of each protein band divided by MGV of 
the corresponding lane’s loading control. Quantification was done using ImageJ (1.8.77).  
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Supplementary Figure 3: Schematic diagram showing amplified regions in the ChIP 
experiments. Arrows depict the primers. TSS – Transcription Start Site.  
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Supplementary Tables 
Supplementary Table S1: Primer Sequences for ChIP experiments 
 
Supplementary Table S2: Primer Sequences for RT-qPCR experiments 
 
 
 
 
 
 
Gene Forward Primer Reverse Primer 
Cyclin D1 5’-TTCGGGATGATTGGAATAGC-3’ 5’-TGTGAGCTGGCTTCATTGAG-3’ 
GAPDH 5’- AGAGAGGGAGGAGGGGAAATG-3’ 5’- AACAGGGAGGAGCAGAGAGCAC -3’ 
MCK 5’-ACCCGAGATGCCTGGTTAT-3’ 5’-AGAGCGAGCTTCTCCTCCAT-3’ 
MyHC 5’-TAAGTCCAATATTAGAGATTCCAATTGAAGAT-3’ 5’-GGTGTGGGGGAGCTGGCTTTTAG-3’ 
MyoG promoter 5’-CTGGAAACGTCTTGATGTGC-3’ 5’-CCATTTAAACCCTCCCTGCT-3’ 
MyoG upstream 5’-CGGGTCCTGTCTGTTTACTACGTT-3’ 5’- AATGCCTTCTGGCACTAGAACCGT-3’ 
Gene Forward Primer Reverse Primer 
Smad7 5′-TCCTGCTGTGCAAAGTGTTC-3′ 5′-TTGTTGTCCGAATTGAGCTG-3′ 
SET 5’-TTACTGACCATTCTGACGCA-3’ 5’-CTGCCCTCTCCTTCTTCATCA-3’ 
MCK 5’-GGAGAAGGGAGGCAATATGAAG-3’ 5’-GGTGCTCGTTCCACATGAA-3’ 
MyHC 5’-TGCCACATCTTGATCTGCTC-3’ 5'-CTCGGCTTCAAGGAAAATTG-3' 
MyoG 5’-CAGCTCCCTCAACCAGGAG-3’ 5’-TGCAGGAGGCGCTGT-3’ 
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Extended Materials and Methods 
Western Blot Analysis Protocol 
Wash Buffer 
 5mL of 10% tween 20  
1L 1X TBS, final concentration is 0.5% 
Transfer Buffer 
100mL of 10X transfer buffer  
100mL methanol 
800mL of ddH2O 
10X Transfer Buffer 
288g glycine 
60.4g Tris base 
1.8L dH2O 
Blocking Buffer 
150mL 1X TBST Wash buffer 
7.5g nonfat powder milk  
Antibody Dilutions - 5mL 
 Antibody volume = Final volume X 
1
dilution ratio 
 X 1000 to Convert to µl 
e.g 1:1000 dilution with final volume of 5mL  
(1/1000) X 5 X 1000 = 5µl of antibody 
 Add antibody volume to 0.05 X 5mL = 0.25g of powder milk 
 And 5mL of 1X TBST (also called wash buffer) 
Western Sample preparation  
1. Add a fifth of your lysate volume of 5X SDS-loading 
2. Vortex and denature proteins at 95°C for 5min 
3. Spin at max 14,000rpm at 4°C for 15min to pellet lipids  
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Western Blot overall Protocol 
4. Make separating + stacking gel according to sheet in the lab, wait 1 hour at least to 
polymerize 
5. Place gel inside the plastic cassette, place another on the other side to stop the buffer 
from leaking 
6. Put in 1X Laemli buffer 1, wash wells with it as well 
7. Load and run gel at 150volts (200volts for a quick run, this will produce a lot of heat) 
8. Activate membrane in 95% methanol 5min prior to placing in sandwich 
9. Create transfer sandwich 
 
10. Wet all filter and sponges in 1X transfer buffer  
11. Wash membrane and gel in transfer buffer 
12. Put sandwich in transfer buffer, place ice container in the cassette, run at 100 volts for 1 
Hour or 30 volts overnight 
13. Wash membrane in wash buffer 
14. Block membrane via blocking buffer for 1Hour 
15. Put in sealed plastic bag with primary antibody, rock for 1 Hour or overnight in 4°C 
16. Wash 3X for 5mins each  
17. Put membrane in a new sealed plastic bag with secondary antibody, rock for 1 hour  
18. Wash membrane 3X for 5mins each  
19. Put equivalent amounts of ECL chemiluminescent bottles. Suggested volume is 500µl of 
each onto the membrane, dry and remove excess  
20. Wait for 30 secs or 1 min, put membrane in between plastic sheet 
21. Place film on top of membrane 
22. Waiting times varies with strength of signal 
23. Fix and Develop Film. 
 
  
Black Anode plastic
Sponge
Filter X 2
Gel
Membrane
Filter X2
Sponge
Red cathode plastic
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Calcium Phosphate (CaPO4) Transfection 
2X HeBS Solution pH 7.15 
16.4g NaCl 
11.9g HEPES 
0.21g Na2HPO4 
700ml ddH2O 
2.5M CaCl2 
36.76g CaCl2—2 H2O 
100ml ddH2O 
CaPO4 Overall Protocol 
1. The day prior to transfection, seed C2C12 cells at 1x105 per plate if the harvest point is 
myoblast stage. If harvest point is myotube stage, seed cells at 2x105 per plate. Put fresh 
growth medium 10% FBS DMEM 3 hours prior to transfection.  
2. For each plate being transfected, mix 25ug of total DNA mass to be transfected, bring 
volume up to 450ul using ddH2O. 
3. Add 500ml of cold 2X HeBS to a 14ml snap cap tube, place on vortexer, leave on to 
vortex at speeds 2 or 3. Don’t press down hard on the vortexer since it will slow down the 
vortex speed.  
4. Add 50ul of CaCl2 to the DNA-H2O mix, bringing total volume to 500ul. Mix well. 
5. Slowly pipette droplets of the CaCl2-DNA-H2O mixture into the 2X HeBS in the 14ml 
scap cap tube while it’s on the vortexer. Drop the DNA-CaCl2 mix within 20seconds of 
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start time. Not too slow. Not too fast. Moderate speed gives the best transfection 
efficiency.  
6. Incubate samples at RT for 25-30min, titrate 3-4 times, add mixture dropwise to the 
surface of the cells. Try to minimize impact force of the droplet by pipetting really close 
to the surface of the cells. 
7. Incubate cells overnight in the incubator, don’t leave the mixture on for over 18-20 hours.  
8. Aspirate medium, wash cells twice with 1X PBS, put fresh 10% FBS DMEM. Leave 
cells to recover for 24H before harvesting or switching to 2% HS DMEM. 
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 Co-Immunoprecipitation Assay 
Wash Buffer 
1mM EDTA (pH 8.0) 
150mM NaCl 
10mM Tris (pH 8.0) 
0.1% NP40 
NP-40 Lysis Buffer 
0.5M PMSF 
0.5M NaV 
Pepstatin A(1ug/ul) 
Leupeptin (10ug/ul) 
Aprotinin (10ug/ul) 
Overall Protocol 
1. Wash cells with cold 1X PBS three times, place NP-40 lysis buffer on top of cells to be 
lysed during scraping and harvesting. 
2. Collect cells/cell lysates and vortex for 10 second intervals every 5min for a total of 
15min. Keep on ice. 
3. Determine protein concentration via a Bradford Assay and use a total of 500ug of total 
protein for each sample. Bring volume of cell lysate up to 650ul for each sample using 
NP40 lysis buffer. 
4. Add appropriate antibody or IgG (total 1ug) and incubate on rocker table at 4°C for 
minimum 1Hr.  
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5. Add 25ul of Protein A/G beads to the lysate-antibody mix. Incubate overnight on rocker 
at 4°C. 
6. The following morning, pellet beads by centrifuging at 3600rpm for 3min at 4°C. 
7. Aspirate supernatant, wash with 500ul of wash buffer three times, mixing and aspirating 
supernatant following centrifugation at 3600rpm for 3min at 4°C. 
8. Add 25ul of 2X Laemmlli loading buffer (with 2% β-mercaptoethanol), mix by vortex, 
followed by boiling at 95°C for 5min. 
9. Spin samples at max 14,000rpm for 1min. Load 20ul of samples into each lane of SDS-
PAGE gel. 
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MyHC Staining (6 well plates) 
1. Aspirate media from the plates, wash three times using 1X PBS. 
2. Incubate cells with 2ml of cold 90% methanol in ddH2O for 5min at -20°C. 
3. Wash three times using 1X PBS for 5 min. 
4. Block in 2ml 5% non-fat skim milk in 1X PBS for 30min on the shaker at 37°C. 
5. Incubate cells on the shaker with 1ml of 5% milk in 1X PBS with 1:20 MF-20 primary 
antibody for 2Hrs at RT. 
6. Wash three times with 1X PBS, 5 minutes each, for a total of 15min on the shaker at RT. 
7. Incubate with secondary antibody diluted 1:1000 in 5% milk in 1X PBS for 1 hour on the 
shaker at RT. 
8. Wash three times with 1X PBS, 5 minutes each, for a total of 15min on the shaker at RT. 
9. Mix 6mg of DAB in 10ml of 1X PBS, add 1:1000 30% hydrogen peroxide. Prepare fresh 
each time. 
10. Incubate with DAB solution for 30min on the shaker at RT. 
11. Wash three times with 1X PBS, 5 minutes each, for a total of 15min on the shaker at RT. 
12. Wash two times with ddH2O, 5 minutes each, for a total of 10min on the shaker at RT. 
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Reverse Transcription 
1. Mix 1ul dNTP, 1ul oligodT, and 100-500ng of RNA (total RNA isolated using QIAGEN 
kit). Bring volume up to a total of 20ul using Rnase free water. 
2. Heat at 65°C for 5min, put on ice. 
3. Add 4ul of 5X First Strand Buffer and 2ul of 0.1M DTT 
4. Incubate at 42°C for 2min. 
5. Add superscript enzyme (0.2-0.5ul) 
6. Mix by tapping, quick spin to collect all the solution at bottom of tube. 
7. Run RT program - 42°C for 50min, 70°C for 15min 
8. Store cDNA at -20°C. 
 
 
